Patient characteristics (N = 31)
| Characteristic . | n . | % . |
|---|---|---|
| Age, y | ||
| Median | 58 | |
| Range | 20-71 | |
| Disease | ||
| AML | 28 | 90.3 |
| MDS | 3 | 9.7 |
| Donor source | ||
| Matched sibling | 13 | 41.9 |
| Matched unrelated | 7 | 22.6 |
| Cord blood | 11 | 35.5 |
| Enrollment criteria for AML | ||
| Myeloablative conditioning regimen (n = 19) | 51.6 | |
| MRD by MPFC | 16 | |
| MRD by FISH | 7 | |
| FHCC score >0 | — | |
| Nonmyeloablative conditioning regimen (n = 9) | 29.0 | |
| MRD by MPFC | 4 | |
| MRD by FISH | 2 | |
| FHCC score >0 | 4 | |
| Enrollment criteria for MDS (R-IPSS) | ||
| Myeloablative conditioning regimen | 3 | 9.7 |
| Nonmyeloablative conditioning regimen | — | — |
| Myeloablative conditioning regimen | ||
| Fludarabine/busulfan/ATG | 5 | 16.1 |
| Fludarabine/cyclophosphamide/thiotepa/TBI | 7 | 22.6 |
| Busulfan/cyclophosphamide | 10 | 32.3 |
| Nonmyeloablative conditioning regimen | ||
| Fludarabine/melphalan | 4 | 12.9 |
| Fludarabine/TBI | 1 | 3.2 |
| Fludarabine/cyclophosphamide/TBI | 4 | 12.9 |
| Treating facility | ||
| University of Colorado | 26 | 83.9 |
| Ohio State University | 5 | 16.1 |
| Follow-up for all patients, d | ||
| Median | 371 | |
| Range | 75-1825 | |
| Follow-up for survivors, d | ||
| Median | 1268 | |
| Range | 411-1825 |
| Characteristic . | n . | % . |
|---|---|---|
| Age, y | ||
| Median | 58 | |
| Range | 20-71 | |
| Disease | ||
| AML | 28 | 90.3 |
| MDS | 3 | 9.7 |
| Donor source | ||
| Matched sibling | 13 | 41.9 |
| Matched unrelated | 7 | 22.6 |
| Cord blood | 11 | 35.5 |
| Enrollment criteria for AML | ||
| Myeloablative conditioning regimen (n = 19) | 51.6 | |
| MRD by MPFC | 16 | |
| MRD by FISH | 7 | |
| FHCC score >0 | — | |
| Nonmyeloablative conditioning regimen (n = 9) | 29.0 | |
| MRD by MPFC | 4 | |
| MRD by FISH | 2 | |
| FHCC score >0 | 4 | |
| Enrollment criteria for MDS (R-IPSS) | ||
| Myeloablative conditioning regimen | 3 | 9.7 |
| Nonmyeloablative conditioning regimen | — | — |
| Myeloablative conditioning regimen | ||
| Fludarabine/busulfan/ATG | 5 | 16.1 |
| Fludarabine/cyclophosphamide/thiotepa/TBI | 7 | 22.6 |
| Busulfan/cyclophosphamide | 10 | 32.3 |
| Nonmyeloablative conditioning regimen | ||
| Fludarabine/melphalan | 4 | 12.9 |
| Fludarabine/TBI | 1 | 3.2 |
| Fludarabine/cyclophosphamide/TBI | 4 | 12.9 |
| Treating facility | ||
| University of Colorado | 26 | 83.9 |
| Ohio State University | 5 | 16.1 |
| Follow-up for all patients, d | ||
| Median | 371 | |
| Range | 75-1825 | |
| Follow-up for survivors, d | ||
| Median | 1268 | |
| Range | 411-1825 |
Five patients with AML met multiple enrollment criteria.
ATG, antithymocyte globulin; FHCC, Fred Hutchinson Cancer Center; FISH, fluorescence in situ hybridization; R-IPSS, revised International Prognostic Scoring System; TBI, total body irradiation.